CD19-redirected Autologous Cells (CAR-CD19 T Cells)
Status:
Unknown status
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
This study is designed for determining the safety and relative engraftment levels of the
redirected autologous T cells transduced with the anti-CD19 lentiviral vector in patients
with CD19-positive B cell leukemia and malignant lymphoma.